アスピリン 81mgと325mgで二次予防アウトカムに違いはなし https://t.co/6l7ygZyMbh
Este ensayo clínico aleatorizado en JAMA arrojó que la aspirina con recubrimiento entérico no es significativamente menos efectiva en prevención de IM o AVC, pero tampoco es significativamente más segura en términos de riesgo de sangrado. #TuitMédico htt
There seems to be an outdated trend of using high-dose aspirin instead of 81 mg aspirin, especially for the purposes of secondary prevention. Why expose a patient to far greater side effects with the no additional antithrombotic effect? https://t.co/LvT7K
RT @javier20ch: ⬇️📚Referencia: https://t.co/C3AEsWQU5o
RT @javier20ch: ⬇️📚Referencia: https://t.co/C3AEsWQU5o
RT @javier20ch: ⬇️📚Referencia: https://t.co/C3AEsWQU5o
⬇️📚Referencia: https://t.co/C3AEsWQU5o
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
@giddygiddyup85 @Shambolika @publicaddress @TheFlatEartherr @SteveHodgeNZ Is aspirin experimental? It's used in clinical tray trials. https://t.co/peimtxLvcr You clearly don't know what a controlled study is, let alone a double-blind, RCT is, which is what
@f2harrell @HiteshiKc @DavidLBrownMD @stephensenn Is this inevitable? Do you this can be overcome (to a degree) by trial designs like ADAPTABLE which functions more like “real world”? https://t.co/LRuBds0WoX
What is the best dose of aspirin for secondary prevention in persons with established atherosclerotic cardiovascular disease? Reference: https://t.co/tXp11YxTi5 https://t.co/xirlL5IWVA
PatientInnen mit einer #kardiovaskulären Erkrankung profitieren von #Acetylsalicylsäure (ASS). In der ADAPTABLE-Studie mit 15.076 Betroffenen waren der Nutzen und Risiko bei einer niedrigen und höheren Dosierung vergleichbar: https://t.co/kyXFW4VFOo
RT @SFPCOfficiel: Clin d'oeil mensuel par la #CJ_SFPC ! 📰 Efficacité comparée de deux dosages d'aspirine dans les maladies cardiovasculaire…
RT @quequesierra: @mz_182 En general, parece que entre una dosis en torno a 300 mg y una dosis en torno a 100 mg no serían muy diferentes…
RT @quequesierra: @mz_182 En general, parece que entre una dosis en torno a 300 mg y una dosis en torno a 100 mg no serían muy diferentes…
RT @SFPCOfficiel: Clin d'oeil mensuel par la #CJ_SFPC ! 📰 Efficacité comparée de deux dosages d'aspirine dans les maladies cardiovasculaire…
Depuis le temps qu’on dit que le Kardegic 160 ne sert à rien.
RT @SFPCOfficiel: Clin d'oeil mensuel par la #CJ_SFPC ! 📰 Efficacité comparée de deux dosages d'aspirine dans les maladies cardiovasculaire…
RT @SFPCOfficiel: Clin d'oeil mensuel par la #CJ_SFPC ! 📰 Efficacité comparée de deux dosages d'aspirine dans les maladies cardiovasculaire…
RT @SFPCOfficiel: Clin d'oeil mensuel par la #CJ_SFPC ! 📰 Efficacité comparée de deux dosages d'aspirine dans les maladies cardiovasculaire…
Clin d'oeil mensuel par la #CJ_SFPC ! 📰 Efficacité comparée de deux dosages d'aspirine dans les maladies cardiovasculaires 👉https://t.co/MrAMGXOZAw 👉 https://t.co/w7nf0z79Cx https://t.co/oyRqmaOH49
RT @AMDApaltc: Dr. Sanford discusses the article, "Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease," at #PALTC22 duri…
RT @AMDApaltc: Dr. Sanford discusses the article, "Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease," at #PALTC22 duri…
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/sQRSrWm2hc
Dr. Sanford discusses the article, "Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease," at #PALTC22 during General Session II. Reference the full article: https://t.co/kZbstLWsho #PALTC22
@OceAlaB Le NEJM, retrouvé que remettait ce point sur le tapis. https://t.co/6zHFaqQ0xt
A few years back I was a Research Assistant for a large, multi-site study with fairly novel methodology. I felt like I made some valuable contributions, so it's pretty cool to see it was published in the New England Journal of Medicine. https://t.co/1AMKRE
32) The more recent ADAPTABLE trial (full text free at https://t.co/HGgyQxcYUr) did not find any major differences in efficacy or safety of 81 mg or 325 mg of #aspirin in terms of either #efficacy or #safety. https://t.co/HeLzOH4ktn
Asprin is still undergoiing trials too. We are still doing experiments with it. How do we know Asprin is safe? https://t.co/ieYRq0wLCZ
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/5MD9mUA6Jn
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/abW0Aou8yE アスピリンジレンマがないことを示したRCT
RT @aayshacader: #ACC21 late-breakers🧵 1/Antiplatelets: Let's start with #aspirin ❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts No diff…
RT @geri_doc: 325mg or 81mg per day of aspirin to prevent progressive heart disease in those with coronary disease? Study shows it does no…
325mg or 81mg per day of aspirin to prevent progressive heart disease in those with coronary disease? Study shows it does not matter--same rate of CV events and bleeding complications Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease h
¿Qué diferencias significativas existen entre el cambio sustancial de dosis de aspirina en pacientes con enfermedad cardiovascular? #PersonaldeSaludIMSS, aquí te compartimos este interesante ensayo clínico 👉 https://t.co/4ntgJINoip https://t.co/5TxPnYCJC1
RT @DamienBarraud: Aspirine 75 (enfin, 81...ils font des trucs bizarres les ricains) = Aspirine 300 (enfin, 325...ils font des trucs bizarr…
#朝活 心血管疾患患者(35%MI/53%PCI既往)でアスピリン使用が81mgと325mgでどう違うか、という検証。有効性については有意差なし(全死因死亡・MI入院・脳卒中入院)。大出血の頻度も差がないが、中止・容量変更は325mgが多い。 つまり使うならば81mgでいいかも。 https://t.co/tWDcP4JsGG
The ADAPTABLE trial reviewed at ACC.21 did not show that aspirin 325 mg was superior to 81 mg daily for patients with atherosclerotic heart disease... -Review by Laura Ross, PA-C, AACC, CLS Read the full article at https://t.co/QHcmVc7iBF https://t.co
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/Kc08zeGyyf
RT @EricTopol: New @NEJM #ACC21 What's the right dose of aspirin for people with heart disease? A large randomized trial with a lot of cro…
RT @SFMU_MS: Aspirine: The primary outcome, a composite of death from any cause, hospitalization due to myocardial infarction, or hospitali…
Aspirine: The primary outcome, a composite of death from any cause, hospitalization due to myocardial infarction, or hospitalization due to stroke, occurred in 7.3% of the 81 mg group and 7.5% of the 325 mg group (not significant). https://t.co/CYchxrfD6t
RT @GlobalPHObserv: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/I2OKhKOKRV
RT @GlobalPHObserv: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/I2OKhKOKRV
RT @GlobalPHObserv: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/I2OKhKOKRV
RT @koruden: 「心血管疾患へのアスピリン、用量による有効性・安全性の差なし」 アテローム動脈硬化性心血管疾患と診断された患者に対してアスピリン1日1回81mg投与群と325mg投与群に割り付け、死亡・心筋梗塞・脳卒中などのアウトカムを分析。両群間で結果に差は認められ…
RT @koruden: 「心血管疾患へのアスピリン、用量による有効性・安全性の差なし」 アテローム動脈硬化性心血管疾患と診断された患者に対してアスピリン1日1回81mg投与群と325mg投与群に割り付け、死亡・心筋梗塞・脳卒中などのアウトカムを分析。両群間で結果に差は認められ…
RT @koruden: 「心血管疾患へのアスピリン、用量による有効性・安全性の差なし」 アテローム動脈硬化性心血管疾患と診断された患者に対してアスピリン1日1回81mg投与群と325mg投与群に割り付け、死亡・心筋梗塞・脳卒中などのアウトカムを分析。両群間で結果に差は認められ…
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/I2OKhKOKRV
RT @koruden: 「心血管疾患へのアスピリン、用量による有効性・安全性の差なし」 アテローム動脈硬化性心血管疾患と診断された患者に対してアスピリン1日1回81mg投与群と325mg投与群に割り付け、死亡・心筋梗塞・脳卒中などのアウトカムを分析。両群間で結果に差は認められ…
In patients with cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin; no differences in cardiovascular events/bleeding between patients assigned to 81 mg or 325 mg of aspirin daily. W/ PittGIM's @MctigueKathleen in @NEJM:
RT @RevistaMFSamfyc: Efectividad comparada de la dosificación de aspirina en la enfermedad cardiovascular https://t.co/LtcEvKtnZo PMID 3399…
Efectividad comparada de la dosificación de aspirina en la enfermedad cardiovascular https://t.co/LtcEvKtnZo PMID 33999548
RT @Susumu_Manabe: アスピリンは81mgでも325mgでも心血管イベント予防効果に差はない。15,076例を対象にした無作為化比較試験の結果。 https://t.co/WmrSN5DNI7 https://t.co/rw3D77oY9T
RT @krychtiukmd: #ACC21 kicking off with #ADAPTABLE, a great pragmatic trial comparing two commonly used aspirin doses in patients with est…
RT @AshuPJadhav: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/SBW6hDsL7v
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
RT @SehsuvarErturk: Bugün #NEJM Kalp-damar hastalığı olan hastalarda Aspirinin farklı dozlarının (81 mg ile 325 mg) etkinliğinin ve kanama…
No significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily. #hematology #meded #foamed #MI #CVD #aspirin #clot https://t.co/06PeYfrrDN
Efectividad comparativa de diferentes dosis de aspirina en enfermedad cardiovascular https://t.co/BHy3P3Cwoi resumen @fisterrae del ensayo publicado en N Engl J Med 2021; 384:1981-1990 https://t.co/PpbAE8n22J
心血管疾患の二次予防のアスピリンは、325mgでも85mgでも効果は変わらない 約1万5千人のRCTを行いアスピリンの容量による効果と副作用を検討したところ、どちらの容量でも心血管イベントの抑制効果と出血の有害事象の数は変わらなかった https://t.co/2xFzNgOyju
少量アスピリンの量は81mgで十分。
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/Q0qG0HYhdW
In ADAPTABLE trial of 15,076 pts with cardiovascular dz, no difference btw Asa 81 vs 325mg in outcomes (death, hospitalization for MI/stroke). High rate of dose switching tho. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM h
RT @ProfMakris: No difference in efficacy or bleeding between 81mg and 325mg of aspirin in patients with established cardiovascular disease…
"In this... trial, which was ... integrated into the routine care of patients with established atherosclerotic cardiovascular disease, there were no significant differences in effectiveness or safety outcomes between 81 mg vs. 325 mg aspirin daily. " https
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/euDtanJyoq
RT @SehsuvarErturk: Bugün #NEJM Kalp-damar hastalığı olan hastalarda Aspirinin farklı dozlarının (81 mg ile 325 mg) etkinliğinin ve kanama…
Bugün #NEJM Kalp-damar hastalığı olan hastalarda Aspirinin farklı dozlarının (81 mg ile 325 mg) etkinliğinin ve kanama riskinin karşılaştırılması. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/t0xXt7rSlW
心血管疾患の予防にアスピリン81mgと325mgに差なし. https://t.co/SOk5Cxbowi
RT @BertrandBio: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/cRxmxxMTBU https://t.co/9ponYTLBbL
Comparative Effectiveness of #Aspirin Dosing in #Cardiovascular Disease . Sin diferencias en sangrados ni eventos cardiovasculares en dosis de 81 y 325 mg https://t.co/6hksbdkEkx
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/yODswZS4rd
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM https://t.co/4cYaqc7yku
No difference in efficacy or bleeding between 81mg and 325mg of aspirin in patients with established cardiovascular disease. Paper in tomorrow's @NEJM. https://t.co/kCBkK1eg14 https://t.co/f2H7lcP9UX
RT @BertrandBio: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/cRxmxxMTBU https://t.co/9ponYTLBbL
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease https://t.co/cRxmxxMTBU https://t.co/9ponYTLBbL
ICYMI: Results of the ADAPTABLE Trial via @NEJM. @UTSWIMchief @UTSWInternalMed @UTSW_IMResRsrch @UTSWCardfellow @thomasjwang1 @DinoKazi https://t.co/PEnRMsa0zO
心血管疾患の患者1万5,000例を対象に、アスピリンの低用量(81mg/日)と高用量(325mg/日)の比較試験を実施。心血管イベントおよび大出血のリスクに関して、両群で有意差がなく、長期アドヒアランスは低用量群で良好だった。 https://t.co/vIxaq09nOG
A recent study shows taking aspirin in high or low doses can lower the chances of suffering a heart attack or stroke for those with cardiovascular disease. https://t.co/qygCjAWZBk
RT @uchida_kawasaki: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease - PubMed https://t.co/996sZBxz7g
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease - PubMed https://t.co/996sZBxz7g
In patients with CV disease, there was no difference in death, hospitalization for MI, or hospitalization for stroke in patients taking 81 mg vs 325 mg. Patients assigned to 325 mg had a higher incidence of dose switching than those assigned to 81 mg. http
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
RT @87HISHAM: كشفت نتائج الدراسة المنتظرة: ADAPTABLE Trial Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease ووجدت:…
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
RT @jvillacastin: Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovas…
Dosis baja, mejor! In patients with established cardiovascular disease, there was no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily. https://t.co/T82zZ60g2
RT @Derek_Leong_RPh: ADAPTABLE trial: In Pts with CAD, no difference between ASA 81 mg/d and 325 mg/d for all-cause death/MI/stroke or majo…